Comparative Pharmacology
Head-to-head clinical analysis: DILOR 400 versus FORADIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DILOR 400 versus FORADIL.
DILOR-400 vs FORADIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phosphodiesterase inhibitor; inhibits PDE4 and PDE5, leading to increased intracellular cAMP and cGMP, resulting in bronchodilation and vasodilation.
Formoterol is a long-acting beta2-adrenergic receptor agonist (LABA) that relaxes bronchial smooth muscle by increasing intracellular cyclic AMP.
400 mg orally every 6 to 8 hours; maximum daily dose 2400 mg.
Inhalation: 12 mcg twice daily (every 12 hours) via Foradil Aerolizer.
None Documented
None Documented
3.1 hours (terminal elimination half-life; may increase in hepatic impairment or congestive heart failure)
Terminal half-life: 7-10 hours. Steady-state achieved within 3-5 days; clinical context: allows twice-daily dosing for bronchodilation.
Renal (70% unchanged), hepatic metabolism (30%)
Renal (60% as unchanged drug and metabolites) and fecal (40% as metabolites).
Category C
Category C
Bronchodilator
Bronchodilator